Spine BioPharma's SB-01 Fails to Meet Primary Endpoint in Phase 3 Trial for Chronic Low Back Pain
核心洞察
Spine BioPharma (搜索)'s Phase 3 MODEL trial evaluating SB-01, a TGF-β (搜索) antagonist for chronic low back pain associated with degenerative disc disease, failed to meet its primary endpoint despite showing clinically meaningful improvements.
The 417-patient randomized controlled trial achieved a 67% success rate with SB-01 at Month 6, but this did not reach statistical significance compared to sham control due to unexpectedly high placebo response rates.
In sites with anticipated sham control responses, SB-01 nearly achieved statistical significance (p=0.051), suggesting the treatment may be effective when placebo effects are controlled.
Spine BioPharma (搜索) announced that its Phase 3 MODEL trial evaluating SB-01, a TGF-β (搜索) antagonist for intradiscal treatment of chronic low back pain associated with degenerative disc disease, failed to meet its primary endpoint of pain intensity and pain-related function at Month 6 compared to sham control. Despite the statistical miss, the treatment demonstrated clinically meaningful improvements and maintained a robust safety profile consistent with earlier studies.
Trial Design and Patient Population
The prospective, randomized, double-blind trial enrolled 417 patients across 30 sites in the United States, utilizing a 1:1 randomization to receive either a single 1.5 ml intradiscal injection of SB-01 or sham control. Both 1- and 2-level degenerative disc disease patients were included, with follow-up assessments conducted at Week 2, Week 6, Month 3, Month 6, and Month 12.
The primary endpoint required patients to achieve both a 2/10-point improvement in Numerical Rating Scale (NRS) for pain intensity and a 15/100-point improvement in Oswestry Disability Index (ODI) for pain-related function to be considered an overall composite success.
Clinical Outcomes and Safety Profile
In the Intent-to-Treat analysis of 417 patients, the SB-01 group achieved primary endpoint success of 67% at Month 6, which, although clinically meaningful, did not reach statistical significance compared to the sham control group. The treatment response was present at early timepoints and proved durable, with 62% of the SB-01 group achieving composite success at Month 12 among the 281 patients who reached that follow-up.
For the secondary endpoint of pain-related function (ODI), the SB-01 group achieved a clinically meaningful success rate of 75% at Month 6 and 71% at Month 12, but these results were not statistically significant compared to sham control. Notably, there was no difference in SB-01 success rates between 1- and 2-level patients at any timepoint.
As observed in the previous Phase 2 clinical trial of 325 patients, SB-01 demonstrated a robust safety profile throughout the Phase 3 study.
Sham Control Response Variability
A key finding was the inconsistent sham control response among sites, with some locations demonstrating much higher than anticipated placebo response rates. Fran Magee, DVM, CTO, stated, "The SB-01 patients responded as anticipated and consistent with the Phase 2 study. In contrast, the sham control response was statistically significantly higher than observed in the Phase 2 study."
The company identified statistically reliable evidence of site-to-site heterogeneity in the sham control response, while the SB-01 response remained homogenous across sites. In a subset analysis of 227 patients at sites with anticipated sham response rates consistent with the Phase 2 study, SB-01 demonstrated superior performance with a composite primary endpoint response of 70% versus 59% for sham control (nominal p=0.051). For the secondary ODI endpoint in this subset, SB-01 achieved 79% success compared to 69% for sham control (nominal p=0.040).
Clinical Significance and Next Steps
Christopher Gilligan, MD, Principal Investigator of the MODEL trial, noted, "This was a landmark, well-designed clinical trial with strict enrollment criteria and very high follow-up rates. The study employed a rigorous composite endpoint requiring patients to achieve both clinically meaningful improvement in both pain intensity and pain-related function."
Marc Viscogliosi, CEO, commented, "Despite our disappointment in missing the primary endpoint, we are quite proud of enrolling and completing this trial under strict FDA guidelines. We ran a solid trial and had we achieved our anticipated sham control group response, the results would have been statistically significant in favor of SB-01."
The company plans to complete data analysis and meet with the FDA to discuss the Phase 3 results alongside earlier Phase 1 and 2 randomized trials to explore potential approval pathways for SB-01 as a treatment for chronic low back pain associated with moderate-severe degenerative disc disease.
About SB-01 Mechanism of Action
SB-01 is a 7-amino acid synthetic peptide that binds to and antagonizes TGF-Beta activity. TGF-Beta is a pleiotropic cytokine that, when present in high concentrations in disease states, can result in negative downstream effects including inflammation, fibrosis, neoinnervation, hyperexcitability of nerves, and cell proliferation. SB-01 modulates TGF-Beta concentration without eliminating it, thereby mitigating these negative downstream effects.